Jump to content

Amlodipine/benazepril

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by KolbertBot (talk | contribs) at 20:22, 23 January 2018 (Bot: HTTP→HTTPS (v481)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Amlodipine/benazepril
Combination of
AmlodipineCalcium channel blocker
BenazeprilACE inhibitor
Clinical data
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
 ☒NcheckY (what is this?)  (verify)

Amlodipine/benazepril, marketed in the U.S. as Lotrel by Novartis and manufactured as a generic drug by Teva and Sandoz, is an antihypertensive medication which combines a calcium channel blocker (amlodipine besilate) with an angiotensin converting enzyme inhibitor (benazepril).[1] This drug, like similar combinations, is prescribed when either agent alone is not sufficient to bring a person's blood pressure down to target range. As a combination agent, Lotrel shares the adverse reaction profile of both of its individual parts.[2][3]

See also

References

  1. ^ Faulkner, Michele A; Hilleman, Daniel E (2005). "Amlodipine/benazepril: fixed dose combination therapy for hypertension". Expert Opinion on Pharmacotherapy. 2 (1): 165–178. doi:10.1517/14656566.2.1.165. ISSN 1465-6566.
  2. ^ Drugs.com: Lotrel
  3. ^ RxList.com: Lotrel


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Amlodipine/benazepril&oldid=821992210"